ID   Caco-2 Cu Pro-R
AC   CVCL_YP11
SY   Cu Pro-R Caco-2; Cu Pro-R
DR   cancercelllines; CVCL_YP11
DR   Wikidata; Q93441262
RX   PubMed=31981602;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_29036; Copper(2+).
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line).
CC   Omics: Proteomics.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0025 ! Caco-2
SX   Male
AG   72Y
CA   Cancer cell line
DT   Created: 12-03-20; Last updated: 10-04-25; Version: 10
//
RX   PubMed=31981602; DOI=10.1016/j.tiv.2020.104773;
RA   O'Doherty, Charles
RA   Keenan, Joanne
RA   Henry, Michael
RA   Meleady, Paula
RA   Sinkunaite, Indre
RA   Clynes, Martin
RA   O'Sullivan, Finbarr
RA   Horgan, Karina
RA   Murphy, Richard
RT   "Characterisation and proteomic profiling of continuously exposed
RT   Cu-resistant variants of the Caco-2 cell line.";
RL   Toxicol. In Vitro 65:104773.1-104773.14(2020).
//